Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.
CME information and select publications here.
Fler avsnitt av Oncology Today with Dr Neil Love
Visa alla avsnitt av Oncology Today with Dr Neil LoveOncology Today with Dr Neil Love med Dr. Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
